Brady Collins
Messenger RNA (mRNA) vaccines are a new type of vaccine that uses mRNA molecules to instruct cells to produce copies of a protein on the outside of a virus, allowing the immune system to recognize and create tools to fight the virus. Currently, the only authorized or approved mRNA vaccines on the market are those for COVID-19, developed by Pfizer-BioNTech and Moderna. However, researchers have been working on mRNA technology for decades, and it has the potential to be used for other diseases and conditions, such as the flu, HIV, and cancer.
| Characteristics | Values |
|---|---|
| Current mRNA vaccines on the market | COVID-19 vaccines from Moderna, Pfizer-BioNTech |
| First mRNA vaccine to be brought to market | COVID-19 vaccine |
| First mRNA product to achieve full FDA approval | Pfizer's COVID-19 vaccine |
| First mRNA vaccines to be authorized by the FDA | Moderna COVID-19 vaccines |
| mRNA vaccines in phase 3 clinical trials | Cytomegalovirus (CMV), Influenza (flu), and respiratory syncytial virus (RSV) |
| mRNA vaccines in development | HIV, Zika, KRAS, Avian influenza, Ebola, Herpes simplex virus 2 (HSV-2), Clostridioides difficile (C.diff) |
| mRNA technology applications | Prevention and treatment of diseases, modifying liver genes to reduce cholesterol levels |
Explore related products
What You'll Learn
How mRNA vaccines work
Messenger RNA, or mRNA, was discovered in the early 1960s, and research into how mRNA could be delivered into cells was developed in the 1970s. However, it wasn't until the COVID-19 pandemic in 2020 that the first mRNA vaccine was brought to market.
MRNA vaccines use groundbreaking biotechnology to help our bodies fight off infectious diseases like COVID-19. They are a preventive treatment that trains the body to fight infectious diseases. They work by giving the body instructions to make a small part of the virus so that the immune system can generate tools to fight an infection if it sees the virus again in the future.
MRNA is a molecule in your cells that copies instructions from your DNA and brings them to your ribosomes (protein-making structures in your cells). Your ribosomes use the instructions on mRNA to create proteins that make your body work. The mRNA in vaccines carries the instructions for making a single part of a pathogen (germ) so that your immune system can recognize it.
MRNA vaccines introduce a piece of mRNA that corresponds to a viral protein, usually a small piece of a protein found on the virus's outer membrane. This allows cells to produce the viral protein. The immune system recognizes that the protein is foreign and produces specialized proteins called antibodies. Antibodies help protect the body against infection by recognizing individual viruses or other pathogens, attaching to them, and marking the pathogens for destruction. Once produced, antibodies remain in the body, even after the body has rid itself of the pathogen, so that the immune system can quickly respond if exposed again.
MRNA vaccines do not enter the nucleus of cells where our DNA is stored and do not alter DNA. The mRNA in vaccines does not stay in the body for long. After the cells make the protein, the mRNA is quickly broken down and flushed out.
Diphtheria, Tetanus, and Pertussis: One Vaccine, Three Diseases
You may want to see also
Explore related products
$11.93 $21.99
The history of mRNA vaccines
Messenger RNA (mRNA) was discovered in the early 1960s, and research into how mRNA could be delivered into cells was developed in the 1970s. In 1978, scientists used fatty membrane structures called liposomes to transport mRNA into mouse and human cells to induce protein expression. However, mRNA was seen as too unstable and expensive to be used as a drug or vaccine for many years.
In the 1990s, the first mRNA flu vaccine was tested in mice, and in 2013, the first mRNA vaccines for rabies were tested in humans. During this time, there was a lot of enthusiasm for the technology, but there were also difficult technical challenges to overcome. The biggest challenge was that mRNA would be quickly degraded by the body before it could deliver its message and be read into proteins in the cells.
The solution to this problem came from advances in nanotechnology, with the development of fatty droplets (lipid nanoparticles) that acted as a protective envelope for the mRNA, allowing it to enter cells. The first mRNA vaccines using these fatty envelopes were developed against the Ebola virus, but it was not commercially developed in the US as the virus was only found in a limited number of African countries.
With the COVID-19 pandemic, mRNA technology finally got its moment, and Pfizer's COVID-19 vaccine became the first mRNA product to achieve full FDA approval in the US. Moderna and Pfizer-BioNTech used lipid nanoparticles to deliver mRNA in their COVID vaccines. The COVID-19 pandemic spurred manufacturers to develop dozens of potential vaccines, bringing tremendous increases in funding.
MRNA vaccines work by introducing a piece of mRNA that corresponds to a viral protein, usually found on the virus's outer membrane. The cells then produce this viral protein, and the immune system recognizes it as foreign, producing antibodies to protect the body against infection.
MRNA technology has proven to be safe and effective, and researchers are now studying how it can be used to develop vaccines for other diseases and cancer.
Chickenpox Vaccine: When Did It Start?
You may want to see also
Explore related products
The future of mRNA vaccines
MRNA vaccine technology has been in development for decades, but it was the COVID-19 pandemic that accelerated its progress. The first mRNA product to achieve full FDA approval in the U.S. was Pfizer's COVID-19 vaccine. Moderna and Pfizer-BioNTech's COVID-19 vaccines also utilized mRNA technology.
The success of mRNA vaccines in preventing SARS-CoV-2 infections has opened up a new era of mRNA vaccines against other infectious diseases. Researchers are already developing mRNA vaccines to protect against other respiratory viruses, such as the flu, and Moderna is exploring its potential to protect against HIV.
The development of fatty droplets (lipid nanoparticles) that wrap and protect mRNA has been a significant advancement, allowing the mRNA to enter cells and be translated into proteins. This technology is being further optimized for future use.
Additionally, the engineering of mRNA to enhance T follicular helper cells in the lymph nodes could potentially create more effective vaccines, although this presents a complex challenge that requires multidisciplinary collaboration.
Overall, the future of mRNA vaccines looks bright, with the potential to revolutionize the treatment of various diseases and improve global health outcomes.
Live Vaccines: Faster Protection Than Dead Vaccines?
You may want to see also
Explore related products
mRNA vaccines vs traditional vaccines
Messenger RNA (mRNA) was discovered in the early 1960s, and research into how mRNA could be delivered into cells was developed in the 1970s. However, the first mRNA vaccine was not brought to market until the COVID-19 pandemic in 2020. The COVID-19 pandemic spurred manufacturers to develop dozens of potential vaccines against SARS-CoV-2, bringing tremendous increases in funding.
MRNA vaccines differ from traditional vaccines in that they teach our cells how to make a small, harmless piece of the virus to trigger an immune response inside our bodies. Traditional vaccines typically require growing large amounts of infectious viruses and then inactivating them, which can take weeks or months. On the other hand, mRNA vaccines can be quickly designed, tested, and mass-produced. They are also safer because they do not contain live viruses.
MRNA vaccines work by giving your body instructions to make a small part of the virus so your immune system can generate tools to fight an infection if it sees the virus again in the future. This process teaches your body how to recognize and destroy the virus.
MRNA vaccines have several advantages over traditional vaccines. Firstly, they can be quickly designed and scaled up, making them highly adaptable to different pathogens. Secondly, the cost of mRNA vaccines is lower than traditional vaccines, and this cost will continue to decrease as the technology expands. Finally, mRNA vaccines are safe and effective, and they do not alter our DNA.
RSV Vaccine: Medicare Advantage Plan Coverage
You may want to see also
Explore related products
mRNA vaccines for diseases other than COVID-19
Messenger RNA, or mRNA, was discovered in the early 1960s, and research into how mRNA could be delivered into cells was developed in the 1970s. The first mRNA flu vaccine was tested in mice in the 1990s, and the first mRNA vaccines for rabies were tested in humans in 2013. However, the COVID-19 pandemic in 2020 brought about the first mRNA vaccine to be brought to market.
The success of the mRNA COVID vaccines has led to companies exploring the technology for other uses. Currently, vaccines for COVID-19 are the only approved mRNA vaccines. However, researchers have been developing mRNA technology for decades, and it has allowed scientists to create safe and effective vaccines faster than ever before. This means that when there is an outbreak of severe illness, we can potentially have the protection of vaccines in a matter of months instead of years.
MRNA molecules may play a role in other future treatments to help treat a variety of diseases. Scientists are investigating other ways to use mRNA technology in vaccines for other infectious diseases and cancer. mRNA vaccine technology is being studied for its potential use in treating the flu, HIV, herpes, and even cancer. Many of these vaccines are in the early stages of human clinical trials, with researchers still figuring out the best dosage and whether they will work.
The first mRNA vaccines were developed against the deadly Ebola virus, but since the virus is only found in a limited number of African countries, it did not have any commercial development in the US.
The Pertussis Vaccine: What's in a Name?
You may want to see also
Frequently asked questions
Yes, there are currently mRNA vaccines for COVID-19 on the market.
mRNA vaccines work by introducing a piece of mRNA that corresponds to a viral protein, usually a small piece of a protein found on the virus's outer membrane. The mRNA in vaccines carries the instructions for making a single part of a pathogen (germ) so that the immune system can recognize it.
Moderna, Pfizer-BioNTech, and Johnson & Johnson are some of the companies that produce mRNA vaccines.
mRNA vaccines have fast development and production times, making them ideal for protection against new infectious diseases and variants of existing ones. They are also safe and effective.
Yes, scientists are investigating other ways to use mRNA technology in vaccines for other infectious diseases and cancer. Researchers at Penn Medicine are using mRNA technology to modify liver genes to permanently reduce cholesterol levels and protect against heart attack and stroke.
